Bayer Pares Dr. Scholl's In Latest Step Toward Core Consumer Portfolio
Bayer follows through on plans to divest Dr. Scholl’s after selling Coppertone business in May to focus on consumer lines such as Aleve oral analgesics, Claritin allergy treatments and Bayer Aspirin. Private equity firm Yellow Wood Partners creating stand-alone company to operate Dr. Scholl's.
You may also be interested in...
Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.
Karo Pharma will pay LEO Pharma €90m for a basket of dermatology and anti-hemorrhoid brands to expand its European footprint.
During Q3, biopharma company fundraising reached $13.3bn, mostly from follow-on public offerings, which again made up the most of those dollars. Despite numerous deals valued at $100m+, M&A activity was the lowest of the year. Many of the biggest partnership deals were centered around the inflammation/immune area.